Format

Send to

Choose Destination
Addiction. 2008 Mar;103(3):462-8. doi: 10.1111/j.1360-0443.2007.02090.x. Epub 2008 Jan 8.

Exposure to opioid maintenance treatment reduces long-term mortality.

Author information

1
National Drug and Alcohol Research Centre, UNSW, Australia. amy.gibson@med.unsw.edu.au

Abstract

AIMS:

To (i) examine the predictors of mortality in a randomized study of methadone versus buprenorphine maintenance treatment; (ii) compare the survival experience of the randomized subject groups; and (iii) describe the causes of death.

DESIGN:

Ten-year longitudinal follow-up of mortality among participants in a randomized trial of methadone versus buprenorphine maintenance treatment.

SETTING:

Recruitment through three clinics for a randomized trial of buprenorphine versus methadone maintenance.

PARTICIPANTS:

A total of 405 heroin-dependent (DSM-IV) participants aged 18 years and above who consented to participate in original study.

MEASUREMENTS:

Baseline data from original randomized study; dates and causes of death through data linkage with Births, Deaths and Marriages registries; and longitudinal treatment exposure via State health departments. Predictors of mortality examined through survival analysis.

FINDINGS:

There was an overall mortality rate of 8.84 deaths per 1000 person-years of follow-up and causes of death were comparable with the literature. Increased exposure to episodes of opioid treatment longer than 7 days reduced the risk of mortality; there was no differential mortality among methadone versus buprenorphine participants. More dependent, heavier users of heroin at baseline had a lower risk of death, and also higher exposure to opioid treatment. Older participants randomized to buprenorphine treatment had significantly improved survival. Aboriginal or Torres Strait Islander participants had a higher risk of death.

CONCLUSIONS:

Increased exposure to opioid maintenance treatment reduces the risk of death in opioid-dependent people. There was no differential reduction between buprenorphine and methadone. Previous studies suggesting differential effects may have been affected by biases in patient selection.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center